Relay Therapeutics Inc
RLAY6.050USD
-0.480-7.35%
收盘 11/07, 16:00（美东）报价延迟15分钟
1.04B总市值
亏损市盈率 TTM
关于 Relay Therapeutics Inc 公司
Relay Therapeutics Inc. 是一家临床阶段的精准医疗公司。该公司专注于加强针对肿瘤和遗传疾病的小分子治疗发现。该公司的 Dynamo 平台集成了一系列计算和实验方法，旨在针对以前难以解决或未得到充分解决的蛋白质靶点进行药物治疗。该公司的主要候选产品包括 RLY-2608、Lirafugratinib (RLY-4008) 和 Migoprotafib (GDC-1971)。RLY-2608 是一种变构、全突变和异构体选择性磷酸肌醇 3 激酶 α (PI3Kα) 抑制剂。RLY-4008 是一种强效、选择性和口服小分子 FGFR2 抑制剂，FGFR2 是一种受体酪氨酸激酶，在某些癌症中经常发生改变。 GDC-1971 是一种 Src 同源区 2 结构域磷酸酶 2 (SHP2) 的抑制剂，用于治疗晚期或转移性实体瘤患者的单一疗法。
Relay Therapeutics Inc简介
公司代码RLAY
公司名称Relay Therapeutics Inc
上市日期Jul 16, 2020
CEODr. Sanjiv K. Patel, M.D.
员工数量261
证券类型Ordinary Share
年结日Jul 16
公司地址60 Hampshire Street
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02139
电话16173708837
网址https://relaytx.com/
公司代码RLAY
上市日期Jul 16, 2020
CEODr. Sanjiv K. Patel, M.D.
Relay Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
暂无数据
地区USD
名称
营收
占比
United States
677.00K
0.00%
业务
地区
暂无数据
股东统计
更新时间: 11月8日 周六
更新时间: 11月8日 周六
持股股东
股东类型
持股股东
持股股东
占比
SB Investment Advisers (UK) Limited
16.10%
Point72 Asset Management, L.P.
7.76%
Commodore Capital LP
7.70%
Casdin Capital, LLC
6.58%
BlackRock Institutional Trust Company, N.A.
6.13%
其他
55.73%
持股股东
持股股东
占比
SB Investment Advisers (UK) Limited
16.10%
Point72 Asset Management, L.P.
7.76%
Commodore Capital LP
7.70%
Casdin Capital, LLC
6.58%
BlackRock Institutional Trust Company, N.A.
6.13%
其他
55.73%
股东类型
持股股东
占比
Hedge Fund
34.94%
Investment Advisor
27.34%
Private Equity
16.87%
Investment Advisor/Hedge Fund
14.05%
Research Firm
1.95%
Individual Investor
1.32%
Venture Capital
1.04%
Sovereign Wealth Fund
0.48%
Family Office
0.44%
其他
1.57%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
457
168.31M
97.11%
-38.09M
2025Q2
460
180.78M
105.44%
-7.40M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
2023Q2
397
136.32M
112.15%
-5.86M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
SB Investment Advisers (UK) Limited
27.90M
16.19%
--
--
Jun 30, 2025
Point72 Asset Management, L.P.
13.45M
7.8%
+2.62M
+24.19%
Jun 30, 2025
Commodore Capital LP
13.35M
7.74%
+3.35M
+33.50%
Jun 30, 2025
Casdin Capital, LLC
11.40M
6.61%
+2.30M
+25.28%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.63M
6.16%
-159.25K
-1.48%
Jun 30, 2025
The Vanguard Group, Inc.
9.35M
5.42%
-2.73M
-22.57%
Jun 30, 2025
Bellevue Asset Management AG
8.23M
4.77%
+853.58K
+11.57%
Jun 30, 2025
Tang Capital Management, LLC
8.07M
4.68%
--
--
Jun 30, 2025
State Street Investment Management (US)
5.20M
3.02%
+43.60K
+0.85%
Jun 30, 2025
Nextech Invest, Ltd.
3.85M
2.23%
--
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.09%
Tema Oncology ETF
0.61%
ALPS Medical Breakthroughs ETF
0.53%
SPDR S&P Biotech ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
Avantis US Small Cap Equity ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.09%
Invesco Nasdaq Biotechnology ETF
0.09%
iShares Biotechnology ETF
0.06%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.09%
Tema Oncology ETF
占比0.61%
ALPS Medical Breakthroughs ETF
占比0.53%
SPDR S&P Biotech ETF
占比0.2%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.11%
Avantis US Small Cap Equity ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.09%
Invesco Nasdaq Biotechnology ETF
占比0.09%
iShares Biotechnology ETF
占比0.06%
Invesco RAFI US 1500 Small-Mid ETF
占比0.06%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
